• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Biote Corp.

    5/13/26 4:30:36 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    biote Corp.

    (Name of Issuer)


    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)




    090683103

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    090683103


    1Names of Reporting Persons

    Bandera Partners LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,065,482.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,065,482.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,065,482.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP Number(s):
    090683103


    1Names of Reporting Persons

    Bylinsky Gregory
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,065,482.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,065,482.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,065,482.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):
    090683103


    1Names of Reporting Persons

    Gramm Jefferson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,065,482.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,065,482.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,065,482.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    biote Corp.
    (b)Address of issuer's principal executive offices:

    1875 W. WALNUT HILL LN #100, IRVING, TX, 75038
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Bandera Partners LLC, a Delaware limited liability company ("Bandera Partners"), Gregory Bylinsky and Jefferson Gramm. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Bandera Partners and Messrs. Bylinsky and Gramm are filing this Statement with respect to the 2,065,482 shares of Class A Common stock, par value $0.0001 per share, of the Issuer (the "Shares") directly held by Bandera Master Fund L.P., a Cayman Islands exempted limited partnership ("Bandera Master Fund"). Bandera Partners is the investment manager of Bandera Master Fund and may be deemed to have beneficial ownership over the Shares held by Bandera Master Fund by virtue of the sole and exclusive authority granted to Bandera Partners by Bandera Master Fund to vote and dispose of such Shares. Messrs. Bylinsky and Gramm are Managing Members of Bandera Partners and may be deemed to beneficially own the Shares held by Bandera Master Fund. The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares that it or he does not directly own. Without limiting the foregoing sentence, Bandera Master Fund specifically disclaims beneficial ownership of the Shares held by it by virtue of its inability to vote or dispose of such Shares.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is 138 Atlantic Avenue, Brooklyn, New York 11201.
    (c)Citizenship:

    Bandera Partners is organized under the laws of the State of Delaware. Each of Messrs. Bylinsky and Gramm is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A common stock, par value $0.0001 per share
    (e)CUSIP No.:

    090683103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    All ownership information reported in this Item 4 is as of the close of business on March 31, 2026. Bandera Partners LLC 2,065,482 Shares Gregory Bylinsky 2,065,482 Shares Jefferson Gramm 2,065,482 Shares
    (b)Percent of class:

    Bandera Partners LLC 6.4% (based on 32,046,352 Shares outstanding as of March 23, 2026, as disclosed in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026) Gregory Bylinsky 6.4% (based on 32,046,352 Shares outstanding as of March 23, 2026, as disclosed in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026) Jefferson Gramm 6.4% (based on 32,046,352 Shares outstanding as of March 23, 2026, as disclosed in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The right to receive dividends from, or the proceeds from the sale of, the Shares reported herein is held by Bandera Master Fund, a private investment fund for which Bandera Partners serves as investment manager. Bandera Partners and Messrs. Bylinsky and Gramm disclaim beneficial ownership of the Shares reported in this statement pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on June 13, 2023.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Bandera Partners LLC
     
    Signature:/s/ Gregory Bylinsky
    Name/Title:Gregory Bylinsky, Managing Member
    Date:05/13/2026
     
    Bylinsky Gregory
     
    Signature:/s/ Gregory Bylinsky
    Name/Title:Gregory Bylinsky
    Date:05/13/2026
     
    Gramm Jefferson
     
    Signature:/s/ Jefferson Gramm
    Name/Title:Jefferson Gramm
    Date:05/13/2026
    Get the next $BTMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    8/7/2025$4.00Buy → Neutral
    B. Riley Securities
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    biote Corp. downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

    8/7/25 7:36:54 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on biote Corp.

    Craig Hallum initiated coverage of biote Corp. with a rating of Buy

    12/16/24 8:50:55 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    B. Riley Securities initiated coverage on biote Corp. with a new price target

    B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

    2/20/24 6:47:29 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    SEC Filings

    View All

    Biote Corp. filed SEC Form 8-K: Leadership Update

    8-K - biote Corp. (0001819253) (Filer)

    6/2/26 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 8-K filed by Biote Corp.

    8-K - biote Corp. (0001819253) (Filer)

    5/18/26 4:30:20 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biote Corp.

    SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)

    5/13/26 4:30:36 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

    Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

    6/1/26 8:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

    Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

    5/28/26 9:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports First Quarter 2026 Financial Results

    Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

    5/6/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/8/25 7:16:54 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/2/25 5:12:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    4/23/25 4:58:23 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Heyer Andrew R

    4 - biote Corp. (0001819253) (Issuer)

    5/14/26 4:10:06 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morris Debra L converted options into 21,407 shares, increasing direct ownership by 43% to 71,562 units (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/13/26 6:17:55 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Cone Stephen Mark

    4 - biote Corp. (0001819253) (Issuer)

    5/13/26 6:08:03 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

    Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

    6/1/26 8:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

    Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

    5/28/26 9:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $BTMD
    Financials

    Live finance-specific insights

    View All

    Biote Reports First Quarter 2026 Financial Results

    Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

    5/6/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules First Quarter 2026 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai

    4/22/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports Fourth Quarter and Full Year 2025 Financial Results

    Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

    3/11/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biote Corp.

    SC 13G/A - biote Corp. (0001819253) (Subject)

    11/12/24 4:15:18 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 2:11:05 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care